tirzepatide patent expiry 2036 As Wegovy patent ends in India, generic drugs flood a niche market The Heavy Price of GLP-1

Doctors say this is posing a health risk to those who truly need it.

GLP-1 medications prescribing trends from 20182024 reveal shifts in semaglutide and tirzepatide use for type 2 diabetes and obesity.

Secondary outcomes included acute HF, acute myocardial infarction and stroke.Results The 3-year risk of all-cause death in the semaglutide group relative to the sitagliptin group was significantly lower (7.2% (943/13 703) vs 9.5% (1196/13 703)

This white paper takes a deep dive into the connection between butyrate, a short-chain fatty acid produced in the gut and its role in enhancing glucagon-like peptide-1 (GLP-1) production.

Learn how it works, what the research shows, and whether it might be right for you.